Communiqués Noxopharm Limited

Actions

NOX

AU000000NOX9

Recherche biotechnologique et médicale

Temps Différé Australian S.E. 05:52:35 29/09/2026			Varia. 5j.	Varia. 1 janv.
0,0570 ^AUD	-5,00%		-6,56%	-38,71%

28/08	Noxopharm Limited publie ses résultats pour l'exercice clos le 30 juin 2026	CI
26/05	Noxopharm affirme que de nouvelles données confirment son potentiel anticancéreux	RE

Communiqués

12/10/23	Noxopharm talks partnership with Hudson Institute of Medical Research	AQ
27/07/22	Noxopharm : June 2022 Quarterly Activities Report and Appendix 4C	PU
07/06/22	Noxopharm : Corporate Presentation	PU
28/04/22	Noxopharm : March 2022 Quarterly Activities Report and Appendix 4C	PU
29/03/22	FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment	BU
08/03/22	Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles	BU
21/02/22	Noxopharm : Appendix 4D and Half Year 2022 Financial Report	PU
09/01/22	Noxopharm : Presents at H.C. Wainwright BioConnect Conference	PU
01/12/21	Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research	BU
16/11/21	Noxopharm : 2021 AGM Corporate Presentation	PU
09/11/21	Noxopharm Announces DARRT-2 Clinical Trial in U.S.	BU
26/08/21	Noxopharm : Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19	BU
25/08/21	Noxopharm : Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients	BU
12/08/21	Noxopharm : Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer	BU
11/05/21	Noxopharm : Veyonda to Begin First-Line Sarcoma Treatment Testing	BU
27/04/21	Noxopharm : Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm	BU
14/04/21	Noxopharm : Files Septic Shock Treatment Patent for Veyonda®	BU
18/03/21	Noxopharm : NOXCOVID Trial Advances to Final Stage	BU
03/12/20	Noxopharm : Independent Discovery Validates Noxopharm’s DARRT Cancer Therapy	BU
12/11/20	Noxopharm : Announces Pilot Study With Bristol Myers Squibb’s Product	BU
23/07/20	Noxopharm : Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’	BU
25/02/20	Noxopharm : FDA Grants IND Approval to Promising Anti-Cancer Agent Veyonda®	BU
14/02/20	Noxopharm : LuPIN Trial Interim Results Indicate Striking Survival Benefit	BU
02/12/19	Noxopharm : Positive DARRT-1 Data in Late-Stage Prostate Cancer	AQ
06/11/19	Noxopharm Announces Appointment of Chief Commercial Officer	GL